17-20 June, 2019
Boston, MA

Microbiome-Drug-Development-partners-purple

Looking To Work With Companies Developing Microbiome Therapeutics?

It’s clear that developing microbiome therapeutics comes with its many challenges and nuances that make it a unique area in comparison with traditional small or large molecule modalities.

Pharma and biotech organizations have often used The Microbiome Movement – Drug Development Summit to evaluate various service providers with unique capabilities in assisting with their development, particularly solutions such as sequencing & bioinformatics, pre-clinical development, formulation, manufacturing and clinical trial design.

Join 250+ senior decision-makers at large pharma and biotech, who are actively seeking to collaborate with organizations that can help them take their candidates to the next phase of development.

If you have capabilities that would benefit our audience, this meeting provides a unique platform to showcase your solutions, generate new business leads and source opportunities for partnerships.

Who Will You Meet?

Let’s Talk – Limited Partnership Opportunities Still Available

Email me at sponsor@hansonwade.com for more information and we can discuss what might be the best way to position your company at this flagship event.

Adam Haras-Gummer
Partnerships Director
Email: sponsor@hansonwade.com
Telephone: +44 (0) 203 141 8727


Hear From Our Existing Partners:

“Hanson Wade has proven to deliver a superior conference where scientific content is consistently emphasized concurrently with business relationship building opportunity. CosmosID has found each event to be an excellent platform for advancement of the microbiome industry, no matter which facet of the field was being promoted.”

CosmosID


In order to further nurture this key business area, ProDigest decided since January 2017 to regularly partner with The Microbiome Movement for the Drug Development Summits in Europe and US.

“This meeting successfully brings together the strategic leaders of companies involved in the development and commercialization of microbiome-based therapeutics, from target discovery and validation of the mechanism of action (i.e. ProDigest’s main expertise) all the way through to clinical trial development. During these events we have made dozens of new contacts and created new strong relationships.

Among them, it is worth to mention the ongoing collaboration with Caelus Health, an Amsterdam-based biotech company developing a new class of LBPs for the reduction of insulin resistance and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome. The initial relationship, simply based on fee-for-service activities, has been further cemented from May 1st 2018, as both parties are partners of PROMISE, a H2020 Eurostars project aimed at the development of a microbiota-based therapy making use of the anaerobic human-derived butyrate-producing bacterium Eubacterium hallii.”

ProDigest